Literature DB >> 30070190

Adaptation of antibiotic treatment to clinical practice guidelines in patients aged ⩾65 years hospitalised due to community-acquired pneumonia.

M A Fernandez-Sierra1, M T Rueda-Domingo1, M M Rodriguez-Del-Aguila1, M J Perez-Lozano2, L Force3, T Fernandez-Villa4, J Astray5, M Egurrola6, J Castilla7, F Sanz8, D Toledo9, A Dominguez9.   

Abstract

Early, conforming antibiotic treatment in elderly patients hospitalised for community-acquired pneumonia (CAP) is a key factor in the prognosis and mortality. The objective was to examine whether empirical antibiotic treatment was conforming according to the Spanish Society of Pulmonology and Thoracic Surgery guidelines in these patients. Multicentre study in patients aged ⩾65 years hospitalised due to CAP in the 2013-14 and 2014-15 influenza seasons. We collected socio-demographic information, comorbidities, influenza/pneumococcal vaccination history and antibiotics administered using a questionnaire and medical records. Bivariate analyses and multilevel logistic regression were made. In total, 1857 hospitalised patients were included, 82 of whom required intensive care unit (ICU) admission. Treatment was conforming in 51.4% (95% confidence interval (CI) 49.1-53.8%) of patients without ICU admission and was associated with absence of renal failure without haemodialysis (odds ratio (OR) 1.49, 95% CI 1.15-1.95) and no cognitive dysfunction (OR 1.71, 95% CI 1.25-2.35), when the effect of the autonomous community was controlled for. In patients with ICU admission, treatment was conforming in 45.1% (95% CI 34.1-56.1%) of patients and was associated with the hospital visits in the last year (<3 vs. ⩾3, OR 2.70, 95% CI 1.03-7.12) and there was some evidence that this was associated with season. Although the reference guidelines are national, wide variability between autonomous communities was found. In patients hospitalised due to CAP, health services should guarantee the administration of antibiotics in a consensual manner that is conforming according to clinical practice guidelines.

Entities:  

Keywords:  Antibiotic treatment; community-acquired pneumonia; correctness; elderly; hospital

Mesh:

Substances:

Year:  2018        PMID: 30070190      PMCID: PMC9506693          DOI: 10.1017/S0950268818002121

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  30 in total

1.  [Community acquired pneumonia. New guidelines of the Spanish Society of Chest Diseases and Thoracic Surgery (SEPAR)].

Authors:  Rosario Menéndez; Antoni Torres; Javier Aspa; Alberto Capelastegui; Cristina Prat; Felipe Rodríguez de Castro
Journal:  Arch Bronconeumol       Date:  2010-09-15       Impact factor: 4.872

2.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

3.  Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance.

Authors:  Sinan Eccles; Celia Pincus; Bernard Higgins; Mark Woodhead
Journal:  BMJ       Date:  2014-12-03

4.  Antibiotic treatment strategies for community-acquired pneumonia in adults.

Authors:  Douwe F Postma; Cornelis H van Werkhoven; Leontine J R van Elden; Steven F T Thijsen; Andy I M Hoepelman; Jan A J W Kluytmans; Wim G Boersma; Clara J Compaijen; Eva van der Wall; Jan M Prins; Jan J Oosterheert; Marc J M Bonten
Journal:  N Engl J Med       Date:  2015-04-02       Impact factor: 91.245

5.  Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-10-12       Impact factor: 17.586

6.  Factors related with the appropriateness of pharmacological treatment in polypathological patients.

Authors:  M Galván Banqueri; E R Alfaro Lara; M Rincón Gómez; P C Rivas Covas; M D Vega Coca; M D Nieto Martín
Journal:  Farm Hosp       Date:  2014-09-16

7.  Community-acquired pneumonia: impact of empirical antibiotic therapy without respiratory fluoroquinolones nor third-generation cephalosporins.

Authors:  J Pradelli; K Risso; F G de Salvador; E Cua; R Ruimy; P-M Roger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-10-02       Impact factor: 3.267

8.  Adherence with national guidelines in hospitalized patients with community-acquired pneumonia: results from the CAPO study in Venezuela.

Authors:  Gur Levy; Mario Perez; Benito Rodríguez; Ana Hernández Voth; Jorge Perez; Martin Gnoni; Robert Kelley; Timothy Wiemken; Julio Ramirez
Journal:  Arch Bronconeumol       Date:  2014-05-05       Impact factor: 4.872

9.  Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Sara Tomczyk; Nancy M Bennett; Charles Stoecker; Ryan Gierke; Matthew R Moore; Cynthia G Whitney; Stephen Hadler; Tamara Pilishvili
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-09-19       Impact factor: 17.586

Review 10.  Risk factors for community-acquired pneumonia in adults in Europe: a literature review.

Authors:  Antoni Torres; Willy E Peetermans; Giovanni Viegi; Francesco Blasi
Journal:  Thorax       Date:  2013-11       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.